Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 9, 2025
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Public Offering Price: $1.20 per share.
- Firm Shares: 12,500,000 shares.
- Price to Company (Firm Shares): $1.1286 per share (after underwriting discount of $0.0714).
- Over-Allotment Option: 45-day option to purchase up to 1,875,000 additional shares.
- Estimated Gross Proceeds: Approximately $15.0 million (firm shares only) or $17.25 million (if option fully exercised).
- Expenses: Company to reimburse underwriters up to $50,000 for legal fees and expenses.
- Underwriters: Canaccord Genuity LLC (sole bookrunner) and Maxim Group LLC (co-manager).
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital. The transaction is expected to close on or about April 11, 2025, subject to customary closing conditions. The offering utilizes an existing shelf registration statement (Form S-3, No. 333-268560) declared effective in December 2022.
Outlook, Risks, and Management Commentary
Management Commentary: The Company issued press releases on April 9, 2025, announcing the offering and its pricing. The proceeds are intended to support the Company's operations, though specific allocation details are not provided in this 8-K text.
Risks and Contingencies:
- The closing is subject to customary conditions contained in the Underwriting Agreement.
- The Company has agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933.
- The final prospectus supplement will be filed with the SEC in accordance with Rule 424.
Investor Verification Checklist
- Verify the final closing date and confirmation of the over-allotment option exercise status.
- Review the final prospectus supplement for detailed use of proceeds and updated risk factors.
- Confirm the actual net proceeds received after deducting the full underwriting discount and all offering expenses.
- Check for any subsequent filings regarding the impact of this capital raise on the Company's cash position and runway.